New cancer drug interaction study: will antibiotics or antifungals change its effects?
NCT ID NCT05372367
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how two common drugs—rifampicin (an antibiotic) and itraconazole (an antifungal)—affect the levels of a new cancer drug called BI 907828 in the blood. It involves 33 adults with advanced solid tumors who have not responded to previous treatments. Participants take BI 907828 alone and then with either rifampicin or itraconazole to see if the combination changes drug levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 907828 (brigimadlin), rifampicin, itraconazole
What this could lead to
If successful, this study will help doctors understand how to safely combine BI 907828 with other common medications, potentially improving treatment for advanced solid tumors.
What could go wrong
This is a small, early-phase study focused on drug interactions, not on proving the drug works. The results may not apply to all patients or lead to a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIO Clara Campal
Madrid, 28050, Spain
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Fundación Jiménez Díaz
Madrid, 28040, Spain
-
Hospital Quiron. I.C.U.
Barcelona, 08023, Spain
-
Hospital Quirónsalud Madrid
Madrid, 28223, Spain
-
Hospital Universitari Vall D Hebron
Barcelona, 08035, Spain
-
Wilrijk - HOSP GZA (St-Augustinus)
Wilrijk, 2610, Belgium